Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline.
Breast cancer is the most common malignancy amongst women in the developed world. For patients with hormone-sensitive breast cancer eligible for adjuvant hormonal therapy, it is important to know if the ovaries are (still) functional or not. Indeed, the choice for a specific adjuvant hormonal treatment depends on the menopausal status of an individual woman. The currently available measures to determine the menopausal status are conflicting. Until better measures become available, we propose a practical guideline enabling an optimal choice of adjuvant hormonal therapy for women with a hormone receptor positive breast cancer taking into account uncertainties about their menopausal status.
Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. f.devos@umcutrecht.nl
F Y F L
FY
De Vos
H W M
HW
van Laarhoven
J S E
JS
Laven
A P N
AP
Themmen
L V A M
LV
Beex
C G J
CG
Sweep
C
C
Seynaeve
A
A
Jager
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008593:Menopause / Q000378:metabolism*; D017410:Practice Guidelines as Topic
D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers